D
BioLargo, Inc.
BLGO
$0.2639
-$0.0002-0.08%
D
Sell
2/18/2025Upgraded
BioLargo, Inc. (BLGO) was upgraded to D- from E+ on 2/18/2025 due to an increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.1 to 0.06.
BioLargo, Inc. (BLGO) was upgraded to D- from E+ on 2/18/2025 due to an increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.1 to 0.06.
E
Sell
10/21/2024Downgrade
BioLargo, Inc. (BLGO) was downgraded to E+ from D- on 10/21/2024 due to a noticeable decline in the growth index, volatility index and solvency index. Operating cash flow declined 131.39% from $481 to -$151, debt to equity increased from 0.08 to 0.1, and EBIT declined 16.64% from -$763 to -$890.
BioLargo, Inc. (BLGO) was downgraded to E+ from D- on 10/21/2024 due to a noticeable decline in the growth index, volatility index and solvency index. Operating cash flow declined 131.39% from $481 to -$151, debt to equity increased from 0.08 to 0.1, and EBIT declined 16.64% from -$763 to -$890.
D
Sell
1/22/2024Upgraded
BioLargo, Inc. (BLGO) was upgraded to D- from E+ on 1/22/2024 due to a significant increase in the growth index, volatility index and total return index. Total revenue increased 84.79% from $1.45M to $2.67M, operating cash flow increased 43.67% from -$1.48M to -$836, and earnings per share increased from -$0.0047 to -$0.0042.
BioLargo, Inc. (BLGO) was upgraded to D- from E+ on 1/22/2024 due to a significant increase in the growth index, volatility index and total return index. Total revenue increased 84.79% from $1.45M to $2.67M, operating cash flow increased 43.67% from -$1.48M to -$836, and earnings per share increased from -$0.0047 to -$0.0042.
E
Sell
10/23/2023Downgrade
BioLargo, Inc. (BLGO) was downgraded to E+ from D- on 10/23/2023 due to a decline in the volatility index, total return index and valuation index.
BioLargo, Inc. (BLGO) was downgraded to E+ from D- on 10/23/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
10/6/2023Upgraded
BioLargo, Inc. (BLGO) was upgraded to D- from E+ on 10/6/2023 due to an increase in the volatility index and valuation index.
BioLargo, Inc. (BLGO) was upgraded to D- from E+ on 10/6/2023 due to an increase in the volatility index and valuation index.
E
Sell
7/27/2023Downgrade
BioLargo, Inc. (BLGO) was downgraded to E+ from D- on 7/27/2023 due to a decline in the volatility index.
BioLargo, Inc. (BLGO) was downgraded to E+ from D- on 7/27/2023 due to a decline in the volatility index.
D
Sell
7/12/2023Upgraded
BioLargo, Inc. (BLGO) was upgraded to D- from E+ on 7/12/2023 due to an increase in the volatility index and total return index.
BioLargo, Inc. (BLGO) was upgraded to D- from E+ on 7/12/2023 due to an increase in the volatility index and total return index.
E
Sell
6/27/2023Downgrade
BioLargo, Inc. (BLGO) was downgraded to E+ from D- on 6/27/2023 due to a decline in the volatility index, total return index and valuation index.
BioLargo, Inc. (BLGO) was downgraded to E+ from D- on 6/27/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
3/14/2023Downgrade
BioLargo, Inc. (BLGO) was downgraded to D- from D on 03/14/2023.
BioLargo, Inc. (BLGO) was downgraded to D- from D on 03/14/2023.
D
Sell
2/23/2023Upgraded
BioLargo, Inc. (BLGO) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index.
BioLargo, Inc. (BLGO) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index.
D
Sell
2/8/2023Downgrade
BioLargo, Inc. (BLGO) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 29.7% from -$724 to -$939.
BioLargo, Inc. (BLGO) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 29.7% from -$724 to -$939.
D
Sell
5/5/2022Upgraded
BioLargo, Inc. (BLGO) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
BioLargo, Inc. (BLGO) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
BioLargo, Inc. (BLGO) was downgraded to D- from D on 4/20/2022 due to a large decline in the growth index and valuation index. Earnings per share declined from -$0.0051 to -$0.0098, and operating cash flow declined 7.38% from -$908 to -$975.
BioLargo, Inc. (BLGO) was downgraded to D- from D on 4/20/2022 due to a large decline in the growth index and valuation index. Earnings per share declined from -$0.0051 to -$0.0098, and operating cash flow declined 7.38% from -$908 to -$975.
D
Sell
11/17/2021Upgraded
BioLargo, Inc. (BLGO) was upgraded to D from D- on 11/17/2021 due to a noticeable increase in the growth index and solvency index. Total revenue increased 53.45% from $464 to $712, operating cash flow increased 24.9% from -$1.21M to -$908, and earnings per share increased from -$0.0067 to -$0.0051.
BioLargo, Inc. (BLGO) was upgraded to D from D- on 11/17/2021 due to a noticeable increase in the growth index and solvency index. Total revenue increased 53.45% from $464 to $712, operating cash flow increased 24.9% from -$1.21M to -$908, and earnings per share increased from -$0.0067 to -$0.0051.
D
Sell
11/8/2021Downgrade
BioLargo, Inc. (BLGO) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index and solvency index.
BioLargo, Inc. (BLGO) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index and solvency index.
D
Sell
11/15/2019Downgrade
BioLargo, Inc. (BLGO) was downgraded to D from D+ on 11/15/2019 due to a noticeable decline in the growth index, efficiency index and total return index. Net income declined 104.96% from -$1.8M to -$3.68M, earnings per share declined from -$0.0123 to -$0.0235, and operating cash flow declined 35.44% from -$982 to -$1.33M.
BioLargo, Inc. (BLGO) was downgraded to D from D+ on 11/15/2019 due to a noticeable decline in the growth index, efficiency index and total return index. Net income declined 104.96% from -$1.8M to -$3.68M, earnings per share declined from -$0.0123 to -$0.0235, and operating cash flow declined 35.44% from -$982 to -$1.33M.
D
Sell
10/15/2019Upgraded
BioLargo, Inc. (BLGO) was upgraded to D+ from D on 10/15/2019 due to a substantial increase in the growth index and valuation index. Earnings per share increased from -$0.0181 to -$0.0123, total revenue increased 17.03% from $364 to $426, and EBIT increased 10.53% from -$1.66M to -$1.49M.
BioLargo, Inc. (BLGO) was upgraded to D+ from D on 10/15/2019 due to a substantial increase in the growth index and valuation index. Earnings per share increased from -$0.0181 to -$0.0123, total revenue increased 17.03% from $364 to $426, and EBIT increased 10.53% from -$1.66M to -$1.49M.
D
Sell
1/26/2017Downgrade
BioLargo, Inc. (BLGO) was downgraded to D from D+ on 1/26/2017 due to a decline in the total return index and valuation index.
BioLargo, Inc. (BLGO) was downgraded to D from D+ on 1/26/2017 due to a decline in the total return index and valuation index.
D
Sell
7/20/2016Upgraded
BioLargo, Inc. (BLGO) was upgraded to D+ from D on 7/20/2016 due to a large increase in the solvency index, total return index and efficiency index. Debt to equity declined from 0.88 to -1.22.
BioLargo, Inc. (BLGO) was upgraded to D+ from D on 7/20/2016 due to a large increase in the solvency index, total return index and efficiency index. Debt to equity declined from 0.88 to -1.22.
D
Sell
3/11/2016Downgrade
BioLargo, Inc. (BLGO) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
BioLargo, Inc. (BLGO) was downgraded to D from D+ on 3/11/2016 due to a significant decline in the volatility index and total return index.
D
Sell
11/20/2015Downgrade
BioLargo, Inc. (BLGO) was downgraded to D+ from C+ on 11/20/2015 due to a significant decline in the efficiency index, valuation index and growth index. Total capital declined 231.15% from -$279.9 to $367.1, and operating cash flow declined 2.25% from -$538.9 to -$526.8.
BioLargo, Inc. (BLGO) was downgraded to D+ from C+ on 11/20/2015 due to a significant decline in the efficiency index, valuation index and growth index. Total capital declined 231.15% from -$279.9 to $367.1, and operating cash flow declined 2.25% from -$538.9 to -$526.8.
C
Hold
11/12/2015Upgraded
BioLargo, Inc. (BLGO) was upgraded to C+ from C on 11/12/2015 due to a significant increase in the total return index and volatility index.
BioLargo, Inc. (BLGO) was upgraded to C+ from C on 11/12/2015 due to a significant increase in the total return index and volatility index.
C
Hold
8/12/2015Upgraded
BioLargo, Inc. (BLGO) was upgraded to C from D+ on 8/12/2015 due to a significant increase in the efficiency index and growth index. Operating cash flow increased 96.32% from -$274.5 to -$538.9, net income increased 65.86% from -$780.4 to -$1.29M, and earnings per share increased from -$0.0094 to -$0.0155.
BioLargo, Inc. (BLGO) was upgraded to C from D+ on 8/12/2015 due to a significant increase in the efficiency index and growth index. Operating cash flow increased 96.32% from -$274.5 to -$538.9, net income increased 65.86% from -$780.4 to -$1.29M, and earnings per share increased from -$0.0094 to -$0.0155.
D
Sell
5/15/2015Downgrade
BioLargo, Inc. (BLGO) was downgraded to D+ from C on 5/15/2015 due to a significant decline in the efficiency index, growth index and solvency index. Debt to equity increased from -0.13 to -0.29, total revenue declined 58.73% from $64.7 to $26.7, and total capital declined 18.94% from -$334.3 to -$271.
BioLargo, Inc. (BLGO) was downgraded to D+ from C on 5/15/2015 due to a significant decline in the efficiency index, growth index and solvency index. Debt to equity increased from -0.13 to -0.29, total revenue declined 58.73% from $64.7 to $26.7, and total capital declined 18.94% from -$334.3 to -$271.
C
Hold
4/21/2015Upgraded
BioLargo, Inc. (BLGO) was upgraded to C from C- on 4/21/2015 due to an increase in the growth index and volatility index.
BioLargo, Inc. (BLGO) was upgraded to C from C- on 4/21/2015 due to an increase in the growth index and volatility index.
C
Hold
4/6/2015Downgrade
BioLargo, Inc. (BLGO) was downgraded to C- from C on 4/6/2015 due to a significant decline in the volatility index, growth index and total return index. Operating cash flow declined 25.88% from -$407.7 to -$302.2, and EBIT declined 13.32% from -$833.4 to -$722.4.
BioLargo, Inc. (BLGO) was downgraded to C- from C on 4/6/2015 due to a significant decline in the volatility index, growth index and total return index. Operating cash flow declined 25.88% from -$407.7 to -$302.2, and EBIT declined 13.32% from -$833.4 to -$722.4.
C
Hold
8/15/2014Upgraded
BioLargo, Inc. (BLGO) was upgraded to C from D+ on 8/15/2014 due to a significant increase in the efficiency index, valuation index and growth index. Total revenue increased 126.88% from $9.3 to $21.1, EBIT increased 39.34% from -$766.9 to -$1.07M, and net income increased 3.77% from -$1.02M to -$1.06M.
BioLargo, Inc. (BLGO) was upgraded to C from D+ on 8/15/2014 due to a significant increase in the efficiency index, valuation index and growth index. Total revenue increased 126.88% from $9.3 to $21.1, EBIT increased 39.34% from -$766.9 to -$1.07M, and net income increased 3.77% from -$1.02M to -$1.06M.
D
Sell
5/16/2014Downgrade
BioLargo, Inc. (BLGO) was downgraded to D+ from C+ on 5/16/2014 due to a significant decline in the efficiency index, valuation index and growth index. Total capital declined 110.88% from -$240 to $26.1, and total revenue declined 38.82% from $15.2 to $9.3.
BioLargo, Inc. (BLGO) was downgraded to D+ from C+ on 5/16/2014 due to a significant decline in the efficiency index, valuation index and growth index. Total capital declined 110.88% from -$240 to $26.1, and total revenue declined 38.82% from $15.2 to $9.3.
C
Hold
3/26/2014Upgraded
BioLargo, Inc. (BLGO) was upgraded to C+ from C on 3/26/2014 due to a substantial increase in the total return index, valuation index and volatility index.
BioLargo, Inc. (BLGO) was upgraded to C+ from C on 3/26/2014 due to a substantial increase in the total return index, valuation index and volatility index.
OTC PK
03/07/2025 3:58PM Eastern
Quotes delayed
